Reference and Traceability for Peptide Drug

Data Characteristics

Pharmacovigilance data for peptide drugs primarily originates from clinical trial reports, real-world evidence (RWE), individual case safety reports (ICSRs), drug labels, and academic literature. This data exists as unstructured text, semi-structured tables, or structured database records. ICSR data may update daily or in real-time. Clinical trial and RWE reports are released upon study milestones or completion. Document structures typically include abstracts, background, methods, results (adverse event incidence, severity, causality), discussion, and conclusions. Key fields include drug name, indication, adverse event terms (using MedDRA codes), onset time, patient characteristics, dosage, treatment duration, concomitant medications, and outcome. Units often include milligrams (mg) or international units (IU) for dosage, days, weeks, or months for time, and percentages or patient-years (PY) for adverse event frequency.

Constraints on "Reference and Traceability" from These Characteristics

The heterogeneous nature of peptide drug data sources requires citation and traceability systems to accommodate multiple data formats. Adverse event reports often contain complex medical terminology and codes (e.g., MedDRA). The citation system must accurately identify and link to original definitions to avoid ambiguity. Varying update frequencies mean the knowledge base needs incremental update and version management capabilities. This ensures real-time accuracy of cited content, especially for rapidly changing ICSR data. Long clinical trial reports and RWE documents challenge text chunking strategies. Semantic integrity and segment length must be balanced to support precise citations. Peptide drugs have specific pharmacokinetic and pharmacodynamic characteristics. Their adverse reactions may be unique. Traceability must distinguish and highlight evidence specific to these drug types. Standardizing fields and units is fundamental for consistent and comparable cited content. The system must preprocess data during ingestion or normalize it during citation.

Configuration Guidelines

Configuration Item	Recommended Value	Rationale
`Chunk size` (Chunk Size)	`500–800 characters`	Balances completeness of peptide drug adverse event descriptions with RAG retrieval efficiency. Prevents semantic loss from over-chunking.
`Chunk Overlap Length` (Chunk Overlap)	`50–100 characters`	Ensures contextual continuity, especially when processing detailed adverse event descriptions. Reduces information fragmentation.
`Recall count` (Retrieval Count)	`Top 5–8 items`	Balances retrieval breadth with model processing load. Ensures coverage of critical information in complex peptide drug adverse reaction reports.
`Similarity threshold` (Similarity Threshold)	`0.75–0.85`	Addresses the need for precise matching of peptide drug-specific terminology and medical codes. Improves citation relevance and reduces noise.
`Rerank result count` (Reranked Count)	`Top 3 items`	Focuses on the most relevant citation evidence. Highlights core information, especially when processing multiple similar adverse event reports.
`MAX_FILE_SIZE_MB`	`200 MB`	Supports ingestion of large clinical trial reports and comprehensive RWE documents. Meets data volume requirements for peptide drugs.

Common Pitfalls

Cited snippets lack complete context, leading to misunderstandings of peptide drug adverse reactions. This usually results from Chunk size (Chunk Size) being too short or Chunk Overlap Length (Chunk Overlap) being insufficient.
Model responses cite irrelevant documents or paragraphs. This may indicate Similarity threshold (Similarity Threshold) is set too low. It fails to effectively filter knowledge chunks directly related to peptide drug adverse events.
Users cannot view original literature details in public-facing responses. This might be due to the frontend configuration show_reference_details field being false or the knowledge base API call not returning the reference_data field.

Verification Steps

Select several typical peptide drug adverse event queries. Check if the model's cited snippets accurately point to detailed descriptions of adverse events, dosage information, and patient outcomes in the original documents. Evaluate the completeness of the cited content.
Verify imported clinical trial reports and ICSR documents in the knowledge base. Check if keyword searches can retrieve relevant adverse event chunks. Confirm chunk content matches original documents, paying special attention to MedDRA codes and specialized terminology accuracy.
Simulate data updates at different times. Test the knowledge base's incremental update mechanism. Confirm the citation system reflects the latest information promptly after new adverse event reports are imported.
Check if the data structure returned by the public-facing API includes the reference_data field. This field should contain key information such as document_id, segment_id, and source_url to support users clicking to view original literature.

Note: The values provided are common starting points. Measure them against your own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.